The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Results of trial of vadastuximab talirine plus hypomethylating agents in AML
Amir Fathi, MD from the Massachusetts General Hospital, Boston, MA discusses the trial of vadastuximab talirine plus hypomethylating agents (azacitidine or decitabine) in acute myeloid leukemia (AML) patients (NCT01902329), which was presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Among the patients treated, the rates of remissions were above 70%; this is a composite remission rate (complete remission, CR and complete remission with incomplete marrow recovery, CRi). Dr Fathi explains that the rates of remission are higher than what would be expected. They presented additional data on even higher-risk groups within this cohort, such as patients with poor risk chromosomal changes or over the age of 75. Even among those patients, the rates of remission and response are high but as of yet, it is not known whether this will translate into improved survival. Dr Fathi explains that a randomized Phase III placebo controlled study called CASCADE will hopefully answer this question; the study compares hypomethylating therapy plus vadastuximab talirine versus hypomethylating plus placebo (NCT02785900).
